Boston Scientific to Acquire Electrophysiology Business
|
By HospiMedica International staff writers Posted on 08 Jul 2013 |
|
Boston Scientific Corporation (Natick, MA, USA) has entered into a definitive agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard (Murray Hill, NJ, USA), for USD 275 million in cash.
The purchase, which is expected to significantly boost Boston Scientific’s expansion in the fast-growing market for advanced EP procedures, provides the company with a range of solutions for cardiac catheter ablations and other EP diagnosis and treatment tools. The addition of Bard EP's strong commercial team and complementary portfolio, including catheter and recording device technologies, would enable Boston Scientific to compete in the global EP market with a stronger and more comprehensive offering. The transaction is expected to close in the second half of 2013, subject to certain regulatory and customary closing conditions.
The C.R. Bard EP division, which will join the Boston Scientific rhythm management unit, is dedicated to the development and delivery of a broad range of devices for the diagnosis and treatment of cardiac arrhythmias. The company offers a full product portfolio, which includes advanced radiofrequency (RF) ablation and mapping catheters, diagnostic catheters, computer-based EP mapping and recording systems, temporary pacing electrodes, and vascular and cardiac access devices.
“We expect this acquisition to accelerate the expansion of our global electrophysiology business and we are pleased to welcome Bard EP to the Boston Scientific team,” said Mike Mahoney, president and CEO of Boston Scientific. “We believe the innovation and global reach that Bard EP delivers will meaningfully advance our position in this fast-growing market, enabling us to more effectively serve the needs of patients who suffer from cardiac arrhythmias.”
“This divestiture is consistent with our strategic plan, which is designed to position our portfolio for accelerated sales growth over time,” said Timothy Ring, chairman and CEO of C. R. Bard. “By exiting the EP business, we believe we can better direct management's attention and our capital resources toward pursuing opportunities where we believe we can achieve sustainable long-term leadership positions and provide attractive growth and returns to shareholders.”
Electrophysiology, a branch of physiology studying the relationship with electric phenomena and bodily processes such as the nervous system, is a USD 2.5 billion global market that is growing at nearly 10% annually.
Related Links:
Boston Scientific Corporation
C.R. Bard
The purchase, which is expected to significantly boost Boston Scientific’s expansion in the fast-growing market for advanced EP procedures, provides the company with a range of solutions for cardiac catheter ablations and other EP diagnosis and treatment tools. The addition of Bard EP's strong commercial team and complementary portfolio, including catheter and recording device technologies, would enable Boston Scientific to compete in the global EP market with a stronger and more comprehensive offering. The transaction is expected to close in the second half of 2013, subject to certain regulatory and customary closing conditions.
The C.R. Bard EP division, which will join the Boston Scientific rhythm management unit, is dedicated to the development and delivery of a broad range of devices for the diagnosis and treatment of cardiac arrhythmias. The company offers a full product portfolio, which includes advanced radiofrequency (RF) ablation and mapping catheters, diagnostic catheters, computer-based EP mapping and recording systems, temporary pacing electrodes, and vascular and cardiac access devices.
“We expect this acquisition to accelerate the expansion of our global electrophysiology business and we are pleased to welcome Bard EP to the Boston Scientific team,” said Mike Mahoney, president and CEO of Boston Scientific. “We believe the innovation and global reach that Bard EP delivers will meaningfully advance our position in this fast-growing market, enabling us to more effectively serve the needs of patients who suffer from cardiac arrhythmias.”
“This divestiture is consistent with our strategic plan, which is designed to position our portfolio for accelerated sales growth over time,” said Timothy Ring, chairman and CEO of C. R. Bard. “By exiting the EP business, we believe we can better direct management's attention and our capital resources toward pursuing opportunities where we believe we can achieve sustainable long-term leadership positions and provide attractive growth and returns to shareholders.”
Electrophysiology, a branch of physiology studying the relationship with electric phenomena and bodily processes such as the nervous system, is a USD 2.5 billion global market that is growing at nearly 10% annually.
Related Links:
Boston Scientific Corporation
C.R. Bard
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Wound Irrigation Solution
Prontosan®
New
Multi-Chamber Washer-Disinfector
WD 390
Latest Business News
- GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
- Medtronic and GE HealthCare Broaden Alliance Across Monitoring and Care Solutions
- Quantum Surgical Acquires NeuWave from Johnson & Johnson
- Medtronic to Acquire Coronary Artery Medtech Company CathWorks
- Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
- FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
- WHX in Dubai (formerly Arab Health) to debut specialised Biotech & Life Sciences Zone as sector growth accelerates globally
- WHX in Dubai (formerly Arab Health) to bring together key UAE government entities during the groundbreaking 2026 edition
- Interoperability Push Fuels Surge in Healthcare IT Market
- Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
- B. Braun Acquires Digital Microsurgery Company True Digital Surgery
- CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
- Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
- Medtronic Partners with Corsano to Expand Acute Care & Monitoring Portfolio in Europe
- Expanded Collaboration to Transform OR Technology Through AI and Automation
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
